sovateltide

Peptideexperimental

Clinical trial activity

10 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
8
Phase 3
2
Phase 4
1

Earliest trial started Jan 1, 2008 (NCT00613691)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • endothelin-1 (8-21), succinyl-(glu(9),ala(11,15))-
  • irl 1620
  • irl-1620
  • l-tryptophan, n-(3-carboxy-1-oxopropyl)-l-alpha-aspartyl-l-alpha-glutamyl-l-alpha-glutamyl-l-alanyl-l-valyl-l-tyrosyl-l-phenylalanyl-l-alanyl-l-histidyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl-l-isoleucyl-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, hemihydrate
  • spi-1620
  • spi-1620
  • spi-1620
  • succinyl-(glu(9),ala(11,15))-endothelin-1 (8-21)
  • succinyl-(glutamyl(9)-alanyl(11,15))-endothelin-1 (8-21)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05955326Phase 4Nov 30, 2023Pharmazz, Inc.
NCT05691244Phase 3Nov 30, 2023Pharmazz, Inc.
NCT05514340Phase 2Oct 31, 2022Pharmazz, Inc.
NCT04047563Phase 3Aug 31, 2019Pharmazz, Inc.
NCT04054414Phase 2Jan 10, 2019Pharmazz, Inc.
NCT04052737Phase 2Mar 23, 2018Pharmazz, Inc.
NCT04046484Phase 2Jan 19, 2018Pharmazz, Inc.
NCT01741155Phase 2May 1, 2013Spectrum Pharmaceuticals
NCT01773785Phase 2Apr 1, 2013Spectrum Pharmaceuticals
NCT00613691Phase 1Jan 1, 2008Spectrum Pharmaceuticals
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Pharmazz, Inc.For profit7732018
Spectrum PharmaceuticalsFor profit3322008
2 organizations
Page 1 / 1